| HS Code | 470856 |
| Api Name | Oseltamivir Veterinary Grade Active Pharmaceutical Ingredient |
| Grade | Veterinary Grade |
| Target Species | Poultry, Swine, and Other Veterinary Animals |
| Dosage Forms Compatible | Tablets, Injections, Capsules, Powders, Granules, Premix, Solutions |
| Chemical Name | Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate |
| Chemical Formula | C16H28N2O4 |
| Molecular Weight | 312.41 g/mol |
| Cas Number | 196618-13-0 |
| Appearance | White to off-white crystalline powder |
| Solubility | Freely soluble in water, methanol, and ethanol; practically insoluble in hexane |
| Melting Point | Approximately 182-184°C (decomposes) |
| Purity | ≥98.5% (HPLC) |
| Mechanism Of Action | Neuraminidase inhibitor; blocks influenza virus replication by preventing viral release from host cells |
| Storage Conditions | Store in a cool, dry place in tightly sealed containers, protected from light and moisture |
| Shelf Life | 24 months when stored under recommended conditions |
| Recommended Dosage Form Excipient Compatibility | Compatible with common excipients used in veterinary solid and liquid formulations |
As an accredited Oseltamivir Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Oseltamivir veterinary-grade API packaged in sealed polyethylene-lined drums, moisture-protected. Net weight: 25 kg per container. |
| Container Loading (20′ FCL) | Oseltamivir veterinary API loaded in 20′ FCL, sealed drums palletized safely, protected for dry, secure transport. |
| Shipping | Oseltamivir Veterinary Grade API is shipped in sealed, moisture-proof drums or sealed bags with COA. Transport under controlled temperature, protected from light and moisture. Classified as pharmaceutical API, non-hazardous but requires secure handling, traceability, and compliance with veterinary drug shipping regulations. |
| Storage | Store Oseltamivir Veterinary Grade API in tightly sealed, original containers in a cool, dry, well-ventilated area at controlled room temperature (15–30°C). Protect from light, moisture, and heat. Avoid exposure to strong oxidizing agents. Keep away from incompatible materials and foodstuffs. Ensure proper labeling and secure access for veterinary use only. |
| Shelf Life | Shelf life: 24 months from manufacture date in sealed original container, stored in a cool, dry place. |
In poultry drinking water medication, oseltamivir phosphate is converted into a water-soluble powder by low-shear blending of the API with anhydrous citric acid, lactose monohydrate, and polyvinylpyrrolidone K30 in a 500 L bin blender operated at 12 rpm for 20 min. The lactose is pre-dried at 40°C in a forced-air oven until loss on drying reaches ≤2.0% w/w because the phosphate salt absorbs atmospheric moisture above 60% RH and forms agglomerates during sachet filling. The blended powder is sieved through a 250 μm stainless steel pharmaceutical screen and discharged into foil-lined sachets under nitrogen flush when ambient relative humidity exceeds 25% RH. A 25 g sachet is reconstituted in 1,000 L of drinking water to produce a target concentration of 15 mg/L oseltamivir phosphate; dissolution testing is performed by adding 25 g of powder to 1,000 mL purified water at 25°C with paddle stirring at 50 rpm. Complete wetting and passage through a 150 μm sieve must occur within 120 s, and absence of visible sediment is verified after 10 min. Dry powder homogeneity is assessed using 10 thief samples taken from the top, middle, and discharge zones of the blender and requires individual assay values between 90.0% and 110.0% of label claim and a relative standard deviation ≤5.0%, consistent with USP <905> expectations for solid intermediates. Chemical stability in the dry powder format requires the pH of the reconstituted solution to remain between 4.5 and 5.5 because alkaline hydrolysis of the ester group accelerates above pH 7.0. Process water used in tank preparation must contain chlorine residuals below 0.5 mg/L because oxidative degradation may generate oseltamivir carboxylate and unspecified related substances above the 0.5% reporting threshold. Carryover in drinking water lines is reduced by installing a final 100 μm in-line filter and flushing the system with potable water for 10 min after each medication cycle. For bulk packaging, the water-soluble powder should meet a total aerobic microbial count of ≤100 CFU/g, a combined yeast and mold count of ≤10 CFU/g per USP <61>, and residual solvent levels not exceeding USP <467> limits. The API and finished powder are stored in sealed containers at 15–25°C and protected from light; exposure to strong oxidizing agents and strongly basic excipients must be avoided.
In integrated swine and poultry feed mills, direct blending of oseltamivir phosphate into a micro-ingredient premix at inclusion rates below 2 kg per tonne often fails carryover specifications because the API particles, with a d90 commonly above 200 μm, segregate from ground corn or wheat middlings during transfer and bin discharge. A two-stage dilution is therefore used: a 5% w/w active pre-blend is first produced by mixing the API with spray-dried lactose monohydrate in a 100 L drum blender at 25 rpm for 15 min, then diluted 1:20 with a low-dust carrier such as corn cob granules or wheat middlings in a 500 L ribbon mixer. Wet granulation is introduced when the intended final premix must remain homogeneous through screw conveyors, bucket elevators, and pneumatic pipelines. The granulation step uses a high-shear mixer with a 120 L bowl, impeller speed of 250 rpm, and chopper speed of 1,800 rpm; a 5% w/w aqueous povidone K30 solution is sprayed at 0.5 kg/min until a wet mass moisture of 18–20% w/w is reached. The wet mass is extruded through a 2.0 mm screen and dried in a fluid-bed dryer with inlet air at 55–65°C until loss on drying is ≤3.0% w/w. The dried granules are sieved to collect 300–1,000 μm particles, with a target bulk density of 0.55–0.65 g/cm³ and a Hausner ratio ≤1.25. Blend uniformity is confirmed by 10 samples assayed by HPLC, requiring a coefficient of variation ≤5.0% and individual recoveries between 90.0% and 110.0% per FDA 21 CFR Part 225 and EU Regulation 2019/4. Carryover into the following batch must be limited to <1.0% of the labeled active concentration, verified by flushing with 10 kg of carrier and assaying the flush material. The premix format should avoid alkaline carriers such as calcium carbonate above 5% w/w because pH values above 7.5 accelerate ester hydrolysis; published data for the stability of oseltamivir phosphate in extruded pelleted feed above 80°C is limited, so incorporation is generally restricted to post-pellet vacuum coating or top dressing. Retention samples are stored at 25°C/60% RH and 40°C/75% RH in accordance with VICH GL3 to monitor oseltamivir carboxylate formation and moisture uptake over the intended shelf life.
Wet granulation is preferred over direct compression when the API fraction exceeds 30% w/w because oseltamivir phosphate shows variable plastic deformation and can produce capping at compression forces below 15 kN on a rotary press. A granulating fluid consisting of 5% w/w povidone K30 in purified water is sprayed at 12 g/min into a high-shear granulator bowl with an impeller speed of 300 rpm and chopper speed of 1,500 rpm until a wet mass torque of 18 N·m is recorded. The granulate is dried in a fluid-bed dryer at 50°C inlet air until loss on drying is 2.0–3.0% w/w and then milled through a 1.0 mm screen. The final tablet blend contains 40% w/w granulate, 45% w/w microcrystalline cellulose PH102, 10% w/w lactose monohydrate, 4% w/w crospovidone, and 1% w/w magnesium stearate; total mixing time after lubricant addition is 3 min at 25 rpm in a V-blender to prevent overlubrication. Tablets are compressed on a 10-station rotary tablet press using 9 mm round concave tooling at 12–18 kN, producing 300 mg tablets with hardness 6–8 kP, friability ≤0.8% after 100 rotations in USP <1216>, and disintegration time ≤5 min in 900 mL water at 37°C using USP <701>. Capsule blends are filled into size 3 hard gelatin capsules at a fill weight of 180 mg and fill volume of 0.30 mL using a dosing-disc capsule filler with tamping pins set to 15 mm penetration depth. Content uniformity testing per USP <905> requires an acceptance value ≤15 for 10 units. Dissolution testing per USP <711> uses apparatus 2 at 50 rpm in 900 mL of pH 1.2 hydrochloric acid at 37°C with a Q value of 75% at 45 min; a second-stage pH 4.5 acetate buffer is used when a veterinary formulation must delay release in the gastric environment. Pre-drying of excipients at 40°C for 4 h is mandatory when ambient relative humidity exceeds 60% because moisture migration from microcrystalline cellulose can change granule glass transition and increase tablet hardness drift during storage. API lots with a d90 above 250 μm require an air-jet milling step to reduce median particle size to 50–100 μm before granulation, otherwise content uniformity failures occur at low unit doses. Avoid blending with amine-based desiccants or strongly alkaline fillers because the phosphate salt can undergo acid-base displacement and reduce chemical stability.
Injectable development requires simultaneous control of sterility assurance and chemical stability. A 10 mg/mL oseltamivir phosphate formulation is prepared in pyrogen-free water with a citrate-phosphate buffer at pH 5.2 and sodium chloride to target osmolality of 290 mOsm/kg. The solution is prefiltered through a 0.45 μm polyvinylidene fluoride membrane and then sterile-filtered through a 0.22 μm polyvinylidene fluoride membrane inside an ISO 14644-1 Class 5 cleanroom. Filling is performed under nitrogen overlay into 10 mL amber type I glass vials with chlorobutyl rubber stoppers and aluminum crimp seals. Terminal sterilization at 121°C for 15 min may increase total related substances beyond the 0.5% threshold if the solution pH exceeds 6.0 at the end of the cycle; therefore terminal sterilization should be validated only after pH mapping of the filled solution at 25°C, 50°C, and 70°C. When steam sterilization cannot meet the related substance limit, aseptic filtration is preferred, with sterility assurance based on EU GMP Annex 1 and media fill validation at 10,000 units per line configuration. Bacterial endotoxins are limited to ≤3.5 EU/mg of oseltamivir phosphate per USP <85>, and the finished injection is tested for sterility using USP <71>. Particulate matter is assessed by light obscuration under USP <787> with limits of ≤6,000 particles per vial at ≥10 μm and ≤600 particles per vial at ≥25 μm. The ester linkage means the formulation must be protected from prolonged exposure to pH below 2.0 or above 8.0; degradation kinetics show a U-shaped pH-rate profile typical of ester prodrugs, so buffering at pH 5.0–5.5 provides the lowest hydrolysis rate within the physiological osmolality window. Batch records should include fill volume tolerance of 10.0 mL ± 0.2 mL, stopper residual moisture ≤0.5% w/w after drying at 105°C for 2 h, and headspace oxygen below 2.0% v/v. Published data for this specific injectable concentration in veterinary species is limited, so stability protocols must follow VICH GL3 with storage at 25°C/60% RH and 40°C/75% RH for 6 months before assigning a commercial shelf life.
| Dosage form | Critical control parameter | Method/regulation | Acceptance range |
|---|---|---|---|
| Water-soluble powder | Reconstituted solution pH | USP <791> | 4.5–5.5 |
| Feed premix granulate | Blend uniformity | FDA 21 CFR Part 225 | CV ≤5.0% |
| Tablet core | Dissolution | USP <711> | Q=75% at 45 min |
| Injectable solution | Bacterial endotoxins | USP <85> | ≤3.5 EU/mg |
| Coated granule | Release at pH 1.2 | USP <711> | ≥85% in 30 min |
| Compounded suspension | Preservative efficacy | USP <51> | 1.0 log reduction at 7 days; no increase at 28 days |
Swine rejection of bitter APIs requires a functional coating applied to granulated cores before top dressing on feed. Oseltamivir phosphate granules are first produced by extrusion-spheronization using 30% w/w API, 35% w/w microcrystalline cellulose spheres, 20% w/w lactose monohydrate, 10% w/w hydroxypropyl cellulose, and 5% w/w croscarmellose sodium; purified water is added to a wet mass of 40–45% w/w. The extrudate is passed through a 1.0 mm screen at 60 rpm and spheronized at 1,000 rpm for 5 min in a radial plate spheronizer. The resulting cores are dried at 50°C in a fluid-bed dryer to loss on drying ≤3.0% w/w and sieved to collect 500–1,000 μm pellets. Coating is performed in a Wurster fluid-bed with a 150 mm bottom spray insert, inlet air at 45°C, product temperature 38–40°C, atomizing air at 1.8 bar, and spray rate 8 g/min. Ethylcellulose 7 cps is applied as a 10% w/w ethanolic solution with triethyl citrate 10% w/w of polymer and talc 30% w/w of polymer until a 5% weight gain is achieved. The coating reduces burst release of the bitter phosphate salt in the oral cavity while still releasing ≥85% of the dose in 30 min at pH 1.2. Taste masking is verified by an electronic tongue using a bitterness score reduction of at least 2.0 log units compared with uncoated granules; this method is preferred over sensory panel data because of animal welfare and operator exposure constraints. Final granules are blended with apple pomace or dextrose at 5% w/w before packaging to improve feed recognition and reduce dust. Sieve analysis per USP <786> shows d50 700 μm, d10 450 μm, and d90 1,000 μm; residual solvent ethanol is limited to ≤0.5% w/w when dried at 40°C for 12 h. Direct addition of coated granules to pelleted feed that will be steam-conditioned above 70°C should be avoided because the ethylcellulose film can crack and create dose dumping; published data for the coating integrity of oseltamivir phosphate granules in hot mash is limited.
In hospital and ambulatory veterinary compounding, bulk oseltamivir phosphate powder is converted into an oral suspension at 15 mg/mL by levigating the API with glycerin in a glass mortar and then incorporating a preservative vehicle consisting of sodium citrate buffer pH 5.0, xanthan gum 0.3% w/v, methylparaben 0.1% w/v, and propylparaben 0.02% w/v. The vehicle is prepared at 25°C using a high-shear homogenizer at 4,000 rpm for 15 min to fully hydrate xanthan gum before API addition. The suspension is passed through a 120 μm stainless steel screen to remove undissolved aggregates, filled into 100 mL amber polyethylene terephthalate bottles with child-resistant closures, and stored at 2–8°C. Beyond-use dating is assigned as 14 days under USP <795> unless a validated stability protocol demonstrates chemical and physical stability beyond this period. The formulation must be shaken before each use, and viscosity measured by a rotational viscometer with a #2 spindle at 30 rpm should remain between 900 and 1,200 mPa·s to ensure acceptable pourability and dose accuracy. Dose uniformity is checked by withdrawing 1 mL samples from the top, middle, and bottom of the bottle after 24 h; assay values must fall within 90.0–110.0% label claim. Preservative efficacy is verified by USP <51> using Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Candida albicans, and Aspergillus brasiliensis; the acceptance criterion is a 1.0 log reduction at 7 days and no increase at 28 days. The bitter taste of oseltamivir phosphate is partially masked by the xanthan gum matrix, but veterinary pharmacists often add sodium saccharin at 0.2% w/v and a banana or malt flavour at 0.5% v/v for companion animal acceptance. The suspension should not be mixed with strongly alkaline antacids or magnesium trisilicate because raising the pH above 7.0 accelerates conversion to oseltamivir carboxylate and reduces the intended prodrug absorption. Published data for this specific veterinary suspension configuration is limited; therefore stability protocols should include pH, assay, related substances, and viscosity at 0, 7, 14, and 28 days under VICH GL3 conditions.
Competitive Oseltamivir Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Oseltamivir phosphate veterinary-grade active pharmaceutical ingredient is supplied as a white to off-white crystalline powder with a molecular formula of C16H28N2O4·H3PO4, a molecular weight of 410.4 g/mol, and a CAS registry number of 204255-11-8. The material is released against a certificate of analysis that includes HPLC assay, related substances, water content by Karl Fischer titration, residue on ignition, residual solvents, particle-size distribution, and bulk/tapped density. The API is intended for further processing into tablets, hard-shell capsules, powders, granules, injectable solutions, oral solutions, and medicated feed premixes. The veterinary-grade designation does not alter the chemical identity of oseltamivir phosphate; it signals that manufacture and release are conducted under current good manufacturing practice acceptable to veterinary regulators, with residual-solvent oversight generally aligned to VICH GL18 rather than solely to ICH Q3C. Analytical method validation follows VICH GL1 and VICH GL2. The product is not a sterile starting material; injectable dosage forms require further processing under aseptic conditions or terminal sterilisation, and the API certificate of analysis should be reviewed for bioburden and endotoxin data. Compendial conformance is assessed using USP <621> for HPLC assay, USP <921> for water content, USP <467> for residual solvents, USP <429> for particle sizing, and USP <616> for bulk and tapped density. Where a veterinary pharmacopoeial monograph exists, the monograph requirements take precedence over supplier specifications.
X-ray powder diffraction and differential scanning calorimetry are used to monitor the crystalline form because solid-state changes can alter dissolution, flow, and compaction. Fourier-transform infrared spectroscopy according to Ph. Eur. 2.2.24 is used for identity testing. The supplier should provide a stability-indicating HPLC method and forced degradation data demonstrating resolution of the phosphate salt from oseltamivir carboxylate and process impurities. System suitability requires a resolution factor not less than 1.5 between critical peak pairs.
Particle-size distribution is measured by laser diffraction according to USP <429> or Ph. Eur. 2.9.31. The same powder lot may be unsuitable for direct compression if the fines fraction is high. On a rotary tablet press fitted with 8 mm to 12 mm round tooling and operated at 30 rpm to 60 rpm, blend flow described by a Carr compressibility index above 30% can produce weight variation exceeding 3% RSD unless glidant and lubricant levels are adjusted. For low-dose tablets with an oseltamivir content below 10 mg per unit, a D90 below 180 µm is used by many solid-dosage developers to reduce segregation and maintain content uniformity under USP <905>; published data for oseltamivir tablet content uniformity in veterinary species is limited. Mixing trials on V-blenders or bin blenders should include sampling at 10 min, 20 min, and 30 min with assay RSD targets not exceeding 5%.
Tablet hardness is measured according to USP <1217> or Ph. Eur. 2.9.8. For veterinary tablets, a target breaking force of 40 N to 80 N is typical for small- to medium-sized tablets, but the value depends on tablet diameter and shape. The tensile strength should be calculated to compare across tooling sizes; a tensile strength below 1.0 MPa may indicate capping risk. Lubricant level, typically magnesium stearate 0.5% w/w to 1.5% w/w, should be minimized because hydrophobic lubricants can reduce disintegration and dissolution. Disintegration is tested according to USP <701> or Ph. Eur. 2.9.1.
| Quality attribute | Tablet/capsule | Injectable solution | Powder/granule/premix |
|---|---|---|---|
| Assay | USP <621>; content uniformity per USP <905> | USP <621>; dose uniformity per USP <905> | USP <621>; blend homogeneity by validated sampling |
| Water content | Karl Fischer per USP <921> | Karl Fischer per USP <921>; control residual moisture | Karl Fischer per USP <921>; moisture ingress control |
| Endotoxin | Not required for non-sterile oral solids | USP <85> or Ph. Eur. 2.6.14 | Not required unless feed premix is sterile |
| Sterility | Not required | USP <71> or Ph. Eur. 2.6.1 | Not required |
| Particle size | USP <429> or Ph. Eur. 2.9.31 | Not applicable for true solutions | Sieve analysis per USP <786> or Ph. Eur. 2.9.12 |
| Elemental impurities | USP <232>/<233> or Ph. Eur. 2.4.20 | USP <232>/<233> or Ph. Eur. 2.4.20 | USP <232>/<233> or Ph. Eur. 2.4.20 |
| Residual solvents | VICH GL18 / ICH Q3C | VICH GL18 / ICH Q3C | VICH GL18 / ICH Q3C, species-specific correction |
For wet granulation on a high-shear mixer with fluid-bed drying at an inlet air temperature of 55°C to 65°C, the drying endpoint is defined by loss on drying below 2.0% w/w and granule moisture by Karl Fischer below 1.5% w/w. If granule moisture exceeds the endpoint, tablet capping and sticking to upper punches may occur during compression. Dry granulation by roller compaction at roll force 3 kN/cm to 8 kN/cm can improve flow without adding water, but compact hardness and ribbon density must be controlled to avoid overcompaction and loss of tablet reworkability. Capsule filling on automatic dosator or tamping-pin machines requires good powder plug formation; a compressibility index below 25% is generally preferred. The same API lot used in a premix may require a larger D50 to reduce dusting and improve flow, or a finer D50 to improve distribution in a carrier.
Hard-shell capsules may be filled with powder blends or granules; fill weight is controlled by dosator or tamping-pin equipment. API particle size above 500 µm can cause inconsistent plug formation on dosator machines; a D90 below 300 µm reduces this variability. The powder blend should be tested for bulk density, tapped density, compressibility index, and Hausner ratio according to USP <616>.
Injectable dosage forms require the API to be low in bioburden and bacterial endotoxins even when terminal sterilisation is planned, because endotoxins are not removed by heat. The API certificate of analysis should include endotoxin data generated according to USP <85> or Ph. Eur. 2.6.14. An acceptance limit is derived from the maximum animal dose and the route of administration; the parenteral limit calculation follows the principle K/M, where K is 5 EU/kg for intravenous products in humans, and M is the maximum animal dose in kg per hour. Veterinary injectable limits are product- and species-specific; the same calculation principle applies. Sterile filtration through a 0.22 µm membrane can be used before aseptic filling, but filter compatibility with oseltamivir phosphate in solution must be validated because adsorption losses can occur with certain nylon membranes. Terminal sterilisation by moist heat at 121°C for 15 min requires thermal stability data; published data for oseltamivir phosphate under autoclave conditions is limited, and formulators should not assume terminal sterilisation is acceptable without solution stress studies. Sterility of the finished injectable product is tested according to USP <71> or Ph. Eur. 2.6.1.
For aqueous injectable solutions, water for injection is used as the solvent. The API is not supplied as a sterile powder; aseptic processing of the filtered solution into depyrogenated vials is required. Bioburden testing of the API before filtration should be performed according to Ph. Eur. 2.6.12 or an equivalent method, with alert and action limits defined by the manufacturing site. Filled vials should be stoppered and sealed; if the product is not terminally sterilised, aseptic filling uses isolator or cleanroom technology. Environmental monitoring and process simulation media fills should comply with EU GMP Annex 1 or equivalent veterinary GMP guidance.
Oral solutions and syrups prepared from oseltamivir phosphate are buffered to a pH within the range established by stability studies. pH is measured according to USP <791> or Ph. Eur. 2.2.3. The phosphate salt provides high aqueous solubility; however, aqueous solutions may degrade by hydrolysis if exposed to pH extremes for extended periods, so a target pH of 3.0 to 5.5 is often evaluated. Preservatives used in oral liquids should be assessed for chemical compatibility with oseltamivir phosphate; benzalkonium chloride is not required in single-dose veterinary oral syringes and may interfere with assay recovery in some HPLC methods. The absence of published data for every preservative combination means that forced degradation and preservative efficacy testing should be performed according to USP <51> and Ph. Eur. 5.1.3.
Solution formulations require pH measurement according to USP <791> or Ph. Eur. 2.2.3. Oseltamivir phosphate is a salt of a weakly basic drug; its aqueous solution pH depends on concentration and neutralisation during manufacture. Buffering species such as citrate, acetate, and phosphate may be used, but phosphate buffers should not be combined with calcium-containing diluents because precipitation of calcium phosphate can occur. The final solution should be evaluated under forced degradation conditions including acid, base, oxidative, thermal, and photolytic stress as described in VICH GL5. Oxidative degradation may be managed with an antioxidant such as sodium metabisulfite at low concentration, but sulfite sensitivity in the target species must be considered. The ester linkage in oseltamivir phosphate is subject to hydrolytic cleavage to oseltamivir carboxylate; therefore, the formulation must be protected from prolonged exposure to high temperature and high pH. Stability studies should include assay, related substances, pH, colour, and preservative content at 25°C/60% RH long-term and 40°C/75% RH accelerated conditions for oral liquids, with tight container closure systems.
For oral suspension, the API is often dispersed in a suspending medium rather than fully dissolved if the dose is low and stability is improved by partial solubility. Viscosity control with xanthan gum or microcrystalline cellulose/carboxymethylcellulose sodium is measured by rotational viscometer. The viscosity range that maintains pourability and dose uniformity depends on the suspending agent, but a typical target for oral suspensions is 100 mPa·s to 500 mPa·s at 25°C using a Brookfield viscometer at 20 rpm. Batch-to-batch viscosity differences can affect dose delivery with oral syringes. Published data for oseltamivir oral suspension rheology is limited; rheological optimization should be performed using full factorial designs.
Dissolution testing for tablets and capsules is performed according to USP <711> or Ph. Eur. 2.9.3 using apparatus 2 paddle or apparatus 1 basket. Because oseltamivir phosphate is highly soluble, a dissolution medium of 0.1 M hydrochloric acid or acetate buffer at pH 4.5 is often used; acceptance criteria depend on the finished product specification. For veterinary products, dissolution should be run using sink conditions and validated HPLC detection.
Residual-solvent compliance under VICH GL18 and ICH Q3C is especially important for feed premix and granule applications because animals may consume large amounts of product relative to body mass. Class 3 solvents such as ethanol and acetone are typically restricted to 50 mg/day in human exposure terms; extrapolation to avian, swine, and bovine species requires species-specific correction factors. The API is packaged in food-grade LDPE liners inside fibre drums; desiccant is added when moisture-sensitive. Long-term storage at 25°C/60% RH and accelerated storage at 40°C/75% RH follows VICH GL3. The container closure system should be qualified for moisture ingress and volatile-solvent migration.
For dry powders and granules for oral administration, granule size distribution is measured by sieve analysis according to USP <786> or Ph. Eur. 2.9.12. The granule fraction between 180 µm and 710 µm is often used for oral granules, but the exact range is product-specific. Extrusion-spheronization may be used to produce uniform pellets; extruder screen size and spheronization speed must be qualified because oseltamivir phosphate blends can become sticky if the moisture content rises above 1.5% w/w during processing.
Medicated feed premixes and granules are prepared by stepwise dilution with carriers such as lactose monohydrate or corncob fractions. Blend homogeneity is evaluated by sampling from at least 10 locations across the blender; an assay RSD below 5% is typically required by national guidelines for medicated feed. The API should have consistent bulk density to avoid segregation during transport; carrier particle size and density should be matched to the API. Dusting is controlled by adding food-grade mineral oil or vegetable oil at 0.5% w/w to 1.0% w/w; however, oil addition can reduce dissolution of the API if not dispersed properly. Published data for oseltamivir phosphate premix stability in all feed matrices is limited; the formulator should commission compatibility studies with individual feed components.
Oseltamivir phosphate is a neuraminidase inhibitor prodrug. After administration, ester hydrolysis by carboxylesterases forms oseltamivir carboxylate, which inhibits influenza virus neuraminidase and prevents viral budding. Amantadine hydrochloride and rimantadine hydrochloride act on the M2 ion channel, not on neuraminidase. Consequently, the veterinary-grade API is not interchangeable with amantadine at the formulation or clinical level. The resistance profile also differs: oseltamivir resistance is associated with neuraminidase substitutions such as H275Y in N1 subtypes, whereas M2 blockers select for mutations in the M2 transmembrane domain. The two substances cannot be substituted without new efficacy and safety data in the target species. Published species-specific pharmacokinetic data for oseltamivir in veterinary patients is limited; regulatory approval and withdrawal periods must be established for each species and production class. The API is not active against non-influenza viruses, and its use in animals should be limited to influenza virus strains for which susceptibility has been demonstrated.
In avian influenza control, oseltamivir phosphate has been studied in poultry, but the absence of harmonised maximum residue limits means that food-producing animal use requires careful regulatory review. The phosphate salt is not a feed additive for growth promotion; it is an antiviral active ingredient intended for prescription or controlled veterinary use.
